Cargando…

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine immunogenicity varies between individuals, and immune responses correlate with vaccine efficacy. Using data from 1,076 participants enrolled in ChAdOx1 nCov-19 vaccine efficacy trials in the United Kingdom, we found that inter-indi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mentzer, Alexander J., O’Connor, Daniel, Bibi, Sagida, Chelysheva, Irina, Clutterbuck, Elizabeth A., Demissie, Tesfaye, Dinesh, Tanya, Edwards, Nick J., Felle, Sally, Feng, Shuo, Flaxman, Amy L., Karp-Tatham, Eleanor, Li, Grace, Liu, Xinxue, Marchevsky, Natalie, Godfrey, Leila, Makinson, Rebecca, Bull, Maireid B., Fowler, Jamie, Alamad, Bana, Malinauskas, Tomas, Chong, Amanda Y., Sanders, Katherine, Shaw, Robert H., Voysey, Merryn, Snape, Matthew D., Pollard, Andrew J., Lambe, Teresa, Knight, Julian C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873562/ https://www.ncbi.nlm.nih.gov/pubmed/36228659 http://dx.doi.org/10.1038/s41591-022-02078-6

Ejemplares similares

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
por: Costa Clemens, Sue Ann, et al.
Publicado: (2023)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
por: Marchevsky, Natalie Gabrielle, et al.
Publicado: (2022)

Why do breakthrough COVID-19 infections occur in the vaccinated?
por: Maclean, Patrick, et al.
Publicado: (2021)

The Design and Analysis of Seroefficacy Studies for Typhoid Conjugate Vaccines
por: Liu, Xinxue, et al.
Publicado: (2019)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
por: Folegatti, Pedro M, et al.
Publicado: (2020)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
por: Flaxman, Amy, et al.
Publicado: (2021)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial
por: Li, Grace, et al.
Publicado: (2022)

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
por: Nutalai, Rungtiwa, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 – Authors' reply
por: Voysey, Merryn, et al.
Publicado: (2020)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
por: Voysey, Merryn, et al.
Publicado: (2023)

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
por: Barrett, Jordan R., et al.
Publicado: (2021)

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
por: Feng, Shuo, et al.
Publicado: (2021)

Pneumococcal Serotype-Specific Antibodies Persist through Early Childhood after Infant Immunization: Follow-Up from a Randomized Controlled Trial
por: Trück, Johannes, et al.
Publicado: (2014)

Factors influencing women's attitudes towards antenatal vaccines, group B Streptococcus and clinical trial participation in pregnancy: an online survey
por: McQuaid, Fiona, et al.
Publicado: (2016)

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial
por: Kelly, Eimear, et al.
Publicado: (2023)

An Appraisal of the Clinical Features of Pediatric Enteric Fever: Systematic Review and Meta-analysis of the Age-Stratified Disease Occurrence
por: Britto, Carl, et al.
Publicado: (2017)

Under-detection of blood culture-positive enteric fever cases: The impact of missing data and methods for adjusting incidence estimates
por: Voysey, Merryn, et al.
Publicado: (2020)

Mixed effects approach to the analysis of the stepped wedge cluster randomised trial - accounting for the confounding effect of time
por: Nickless, Alecia, et al.
Publicado: (2015)

Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children: study protocol for an individual participant data meta-analysis of randomised controlled trials
por: Voysey, Merryn, et al.
Publicado: (2016)

Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates
por: Voysey, Merryn, et al.
Publicado: (2017)

Computing threshold antibody levels of protection in vaccine clinical trials: An assessment of methodological bias
por: Voysey, Merryn, et al.
Publicado: (2018)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
por: Clemens, Sue Ann Costa, et al.
Publicado: (2021)

Universally Immune: How Infection Permissive Next Generation Influenza Vaccines May Affect Population Immunity and Viral Spread
por: Bull, Maireid B., et al.
Publicado: (2021)

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
por: Ramasamy, Maheshi N, et al.
Publicado: (2020)

Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults
por: Lazarus, Rajeka, et al.
Publicado: (2016)

Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial
por: Theiss-Nyland, Katherine, et al.
Publicado: (2019)

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
por: Costa Clemens, Sue Ann, et al.
Publicado: (2022)

Response to Letter to the Editor by Ish et al. entitled ‘COVID-19 vaccine equity—the need of the hour’
por: Maclean, P, et al.
Publicado: (2022)

Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers
por: McCullagh, David, et al.
Publicado: (2015)

Use of weighted multivariate estimates in trials of multi-serotype vaccines to simplify interpretation of treatment differences
por: Voysey, Merryn, et al.
Publicado: (2018)

W-particle breakthrough
por: Lipkin, H J
Publicado: (1983)

Breakthrough!
por: KURNIT, Paul
Publicado: (2010)

Potential global impacts of alternative dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine
por: Aguas, Ricardo, et al.
Publicado: (2021)

Mixed effects approach to the analysis of the stepped wedge cluster randomised trial—Investigating the confounding effect of time through simulation
por: Nickless, Alecia, et al.
Publicado: (2018)

Diagnostic accuracy of Fever-PAIN and Centor criteria for bacterial throat infection in adults with sore throat: a secondary analysis of a randomised controlled trial
por: Seeley, Anna, et al.
Publicado: (2021)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
por: Sharpe, Hannah R., et al.
Publicado: (2022)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
por: Emary, Katherine R W, et al.
Publicado: (2021)

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
por: Hillson, Kushalinii, et al.
Publicado: (2021)

Breakthroughs put the bite on malaria.
por: Tenenbaum, David J
Publicado: (2002)

LEP breakthrough
Publicado: (1985)

Cannot write session to /tmp/vufind_sessions/sess_9lb8r23tger7h5eoa91rtd28s9